Monday, May 11, 2026
ADVT 
National

Health Canada approves 2nd generic version of Ozempic-and it's Canadian

Darpan News Desk The Canadian Press, 01 May, 2026 12:10 PM
  • Health Canada approves 2nd generic version of Ozempic-and it's Canadian

Health Canada has approved the second generic version of brand-name Ozempic, this one manufactured by Canadian company Apotex.

The authorization comes just three days after Health Canada approved the first generic semaglutide — the active ingredient in Novo Nordisk's Ozempic — made by Dr. Reddy's Laboratories in India. 

The injectable medications are approved for the treatment of Type 2 diabetes in adults, but Ozempic is often prescribed off-label for weight loss. 

Canada is the first of the G-7 countries to authorize generic semaglutide. 

Apotex is a global pharmaceutical company headquartered in Toronto. 

Many people without drug coverage have been eagerly waiting for generic semaglutide because the brand name original can cost hundreds of dollars a month.

How much cheaper generic semaglutide will be than Ozempic depends on how many generic options are approved and hit the market.

According to the pricing structure of the pan-Canadian Pharmaceutical Alliance, the first generic medication could cost 75 to 85 per cent of the brand name. Once a second medication enters the market, the price for both drops to 50 per cent. When there are three or more generic products available in Canada, the cost would decrease to about 35 per cent of brand-name Ozempic's price.

Picture Courtesy: THE CANADIAN PRESS/Joe O'Connal

MORE National ARTICLES

128-year-old shipwreck on Vancouver Island charred by fire

128-year-old shipwreck on Vancouver Island charred by fire
A shipwreck that has been part of Vancouver Island's history for more than a century is a charred skeleton after a fire earlier this month.

128-year-old shipwreck on Vancouver Island charred by fire

Canada pledges $4.3B in support for Ukraine as Carney, Zelenskyy meet at G7

Canada pledges $4.3B in support for Ukraine as Carney, Zelenskyy meet at G7
Prime Minister Mark Carney outlined $4.3 billion in new support for Ukraine's defence as he met with Ukrainian President Volodymyr Zelenskyy on the sidelines of the G7 summit in Alberta on Tuesday.

Canada pledges $4.3B in support for Ukraine as Carney, Zelenskyy meet at G7

Alberta doctors association raises concerns over premier limiting free COVID vaccines

Alberta doctors association raises concerns over premier limiting free COVID vaccines
The organization representing Alberta doctors is joining health-care unions in raising concerns over Premier Danielle Smith’s decision to charge most Albertans for a COVID-19 vaccination this fall.

Alberta doctors association raises concerns over premier limiting free COVID vaccines

Lack of appropriate safeguards led to 23andMe data breach, joint investigation finds

Lack of appropriate safeguards led to 23andMe data breach, joint investigation finds
Inadequate security measures opened the door to a data breach discovered two years ago at genetic testing company 23andMe, Canada's privacy watchdog says.

Lack of appropriate safeguards led to 23andMe data breach, joint investigation finds

Military police watchdog says military police still resisting civilian oversight

Military police watchdog says military police still resisting civilian oversight
The Military Police Complaints Commission says resistance to civilian oversight in the Canadian Forces Provost Marshal's office "worsened" last year.

Military police watchdog says military police still resisting civilian oversight

Carney's task at G7 will be to keep the group alive as experts question the outcome

Carney's task at G7 will be to keep the group alive as experts question the outcome
As Prime Minister Mark Carney gets ready to host U.S. President Donald Trump and other leaders at the G7 summit in Alberta, analysts say Canada's most important goal will be to keep the group from falling apart — even if that means not issuing a joint statement.

Carney's task at G7 will be to keep the group alive as experts question the outcome